EUCTR2013-000797-30-DK进行中（未招募）1 期
Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation - INSPIRE-AF
Department of Medical Research, Odense University Hospital, Svendborg Hospital0 个研究点开始时间: 2013年10月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients = 18 years of age, male or female.
- •Signed written informed consent.
- •Paroxysmal atrial fibrillation on one or more occasions, detected on 12-lead ECG or Holter monitoring with each AF-episode lasting = 30 seconds, within the last 12 months prior to the screening visit, or persistent AF on one or more occasions that has been direct current (DC) cardioverted within the last 12 months prior to the screening visit.
- •Patients with CHA2DS2-VASc score = 1 will be encouraged to start anticoagulant treatment, but will not be excluded if there are reasonable reasons not to, i.e. risk of bleeding. Patients can choose between standard anticoagulation therapies, i.e. warfarin or non vitamin-K oral anticoagulants (NOAC) such as dabigatran, apixaban and rivaroxaban.
- •Women with childbearing potency must use effective contraception (e.g. implants, hormonal depot injections, combined oral contraceptives, intra-uterine devices or vasectomized partner). Men enrolled in this study must agree to use adequate barrier birth control measures during the treatment period of the study. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Chronic atrial fibrillation.
- •Previous radiofrequency ablation for atrial fibrillation or previous surgical treatment of atrial fibrillation, i.e. MAZE or His-ablation.
- •Heart failure (New York Heart Association (NYHA) class = II and/or LVEF less than 40%).
- •Severe coronary artery disease (acute myocardial infarction within 6 months prior to the screening visit, previous coronary artery bypass graft (CABG) or stabile angina pectoris (Canadian Cardiovascular Society (CCS) class =II).
- •Stroke or transient ischemic cerebral attack within 6 months prior to the screening visit.
- •Pregnant women or women of childbearing potential not on adequate birth control. Only women with a highly effective method of contraception (oral contraception, intra-uterine device or sterile women) can be randomized.
- •Presence of severe and hemodynamically significant valvular heart disease.
- •Any disease that limits life expectancy to less than 1 year.
- •Hepatic insufficiens classified as Child-Pugh B or C.
- •Participation in another clinical trial, either within the last 30 days or ongoing.
- •Breastfeeding women.
- •Ongoing therapy with class IC antiarrhythmics (flecainide, propafenone), amiodarone, dronedarone or sotalol.
- •Chronic or acute kidney disease (estimated glomerular filtration rate (eGFR) = 45 ml/min/1,73m2 (4-variable MDRD equation)).
- •Baseline serum potassium > 5,0 mmol/l.
- •Intolerance or contradictions to spironolactone, i.e. latest product information on Spirix®.
- •Intolerance or contradictions to dabigatran (Pradaxa®) i.e. latest product information.
- •Patients who are noncompliant to the medical treatment.
- •Atrial fibrillation that is associated with an acute reversible condition, i.e. heart surgery, untreated hyperthyroidism etc.
研究者
相似试验
已完成
4 期
Inhibition of Aldosterone in Patients With Chronic Renal DiseaseKidney Failure, ChronicNCT00430924Lene Boesby42
已完成
不适用
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?Coronary artery diseaseCirculatory SystemISRCTN70010120niversity of Dundee (UK)88
进行中（未招募）
1 期
The effect of aldosterone inhibition on proteinuria in patients with progressive renal disease.Patients with chronic nephropathy and proteinuria over 0,5 g/24 hrs are to be given an inhibitor of aldosterone. Theory tells that aldosterone plays an active role in nephropathy and if that can be inhibited patients with chronic renal diseases may prolong their pre-dialysis period of time.MedDRA version: 8.1Level: SOCClassification code 10038359Term: Renal and urinary disordersEUCTR2006-004411-21-DKOrganisation name was not entered25
已完成
不适用
Effects of aldosterone antagonism on microvascular function in obese individualsNL-OMON45212niversiteit Maastricht60
已完成
3 期
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)ADPKDNCT01853553University of Colorado, Denver61